About Biocytogen
Biocytogen is a company based in Wakefield (United States) founded in 2008 by Yuelei Shen.. Biocytogen has raised $301.11 million across 7 funding rounds from investors including NIH, Orbimed and SDIC. The company has 85 employees as of December 31, 2022. Biocytogen operates in a competitive market with competitors including Interius Biotherapeutics, Applied StemCell, GenOway, Nagi Bioscience and GemPharmatech, among others.
- Headquarter Wakefield, United States
- Employees 85 as on 31 Dec, 2022
- Founders Yuelei Shen
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Biocytogen Pharmaceuticals Beijing
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$301.11 M (USD)
in 7 rounds
-
Latest Funding Round
$10 M (USD), Series D
Jun 22, 2021
-
Investors
NIH
& 11 more
-
Employee Count
85
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Biocytogen
Biocytogen is a publicly listed company on the SSE with ticker symbol 688796 in China, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Funding Insights of Biocytogen
Biocytogen has successfully raised a total of $301.11M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $10 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series D — $10.0M
-
First Round
First Round
(19 Aug 2013)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2021 | Amount | Series D - Biocytogen | Valuation |
investors |
|
| Sep, 2020 | Amount | Series D - Biocytogen | Valuation | CMB International Capital |
|
| Aug, 2019 | Amount | Series D - Biocytogen | Valuation | SDIC Venture Capital Management , China Life Insurance |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Biocytogen
Biocytogen has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, Orbimed and SDIC. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Venture capital investments are managed for innovative company growth.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Biocytogen
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Biocytogen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Biocytogen Comparisons
Competitors of Biocytogen
Biocytogen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Interius Biotherapeutics, Applied StemCell, GenOway, Nagi Bioscience and GemPharmatech, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating multiple diseases
|
|
| domain | founded_year | HQ Location |
Provider of animal and cell line models as tools for drug discovery and diagnostics
|
|
| domain | founded_year | HQ Location |
Provider of transgenic rodent models and customized cell lines for preclinical development
|
|
| domain | founded_year | HQ Location |
Developer of a organism on a chip based technology
|
|
| domain | founded_year | HQ Location |
Humanized models and drug screening technologies are developed for research.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Biocytogen
Frequently Asked Questions about Biocytogen
When was Biocytogen founded?
Biocytogen was founded in 2008 and raised its 1st funding round 5 years after it was founded.
Where is Biocytogen located?
Biocytogen is headquartered in Wakefield, United States.
Who is the current CEO of Biocytogen?
Yuelei Shen is the current CEO of Biocytogen. They have also founded this company.
Is Biocytogen a funded company?
Biocytogen is a funded company, having raised a total of $301.11M across 7 funding rounds to date. The company's 1st funding round was a Series D of $78M, raised on Aug 19, 2013.
How many employees does Biocytogen have?
As of Dec 31, 2022, the latest employee count at Biocytogen is 85.
What does Biocytogen do?
Biocytogen was founded in 2008 and is headquartered in Wakefield, United States. An integrated platform for antibody drug discovery and validation is offered within the biotechnology sector. Animal models are generated, therapeutic antibodies are discovered using RenMab mice, and preclinical studies are conducted in vivo or in vitro. These services support antibody-based therapeutic development for pharmaceutical applications.
Who are the top competitors of Biocytogen?
Biocytogen's top competitors include Applied StemCell, GenOway and Champion Oncology.
Is Biocytogen publicly traded?
Yes, Biocytogen is publicly traded on SSE under the ticker symbol 688796.
Who are Biocytogen's investors?
Biocytogen has 12 investors. Key investors include NIH, Orbimed, SDIC, Lake Bleu Capital, and Octagon Capital.
What is Biocytogen's ticker symbol?
The ticker symbol of Biocytogen is 688796 on SSE.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.